HCB 301
Alternative Names: 2023-3979 Solid Tumors - HanchorBio; HCB-301Latest Information Update: 18 Jul 2024
Price :
$50 *
At a glance
- Originator HanchorBio
- Class Antibodies; Immunoglobulin Fc fragments; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action Programmed cell death-1 ligand-1 inhibitors; Transforming growth factor beta inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 09 Jul 2024 FBD Biologics Limited plans a phase I trial for Solid tumour (Late-stage disease, Second-line therapy or greater) and Hodgkin lymphoma (Late-stage disease, Second-line therapy or greater) in September 2024 (IV) (NCT06487624)
- 27 Jun 2023 Preclinical trials in Cancer in Taiwan (Parenteral) (HanchorBio pipeline, June 2023)